1
|
Russell B, Leech P, Wylie H, Moss CL, Haire A, Enting D, Amery S, Chatterton K, Khan MS, Thurairaja R, Nair R, Malde S, Smith K, Gillett C, Josephs D, Pintus E, Rudman S, Hughes S, Relton C, Van Hemelrijck M. A cohort profile of the Graham Roberts study cohort. Front Oncol 2024; 13:1334183. [PMID: 38264755 PMCID: PMC10803459 DOI: 10.3389/fonc.2023.1334183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 12/11/2023] [Indexed: 01/25/2024] Open
Abstract
Purpose The Graham Roberts Study was initiated in 2018 and is the first Trials Within Cohorts (TwiCs) study for bladder cancer. Its purpose is to provide an infrastructure for answering a breadth of research questions, including clinical, mechanistic, and supportive care centred questions for bladder cancer patients. Participants All consented patients are those aged 18 or older, able to provide signed informedconsent and have a diagnosis of new or recurrent bladder cancer. All patients are required to have completed a series of baseline questionnaires. The questionnaires are then sent out every 12 months and include information on demographics and medical history as well as questionnaires to collect information on quality of life, fatigue, depression, overall health, physical activity, and dietary habits. Clinical information such as tumor stage, grade and treatment has also been extracted for each patient. Findings to date To date, a total of 125 bladder cancer patients have been consented onto the study with 106 filling in the baseline questionnaire. The cohort is made up of 75% newly diagnosed bladder cancer patients and 66% non-muscle invasive bladder cancer cases. At present, there is 1-year follow-up information for 70 patients, 2-year follow-up for 57 patients, 3-year follow-up for 47 patients and 4-year follow-up for 19 patients. Future plans We plan to continue recruiting further patients into the cohort study. Using the data collected within the study, we hope to carry out independent research studies with a focus on quality of life. We are also committed to utilizing the Roberts Study Cohort to set up and commence an intervention. The future studies and trials carried out using the Roberts Cohort have the potential to identify and develop interventions that could improve the prevention, diagnosis, and treatment of bladder cancer.
Collapse
Affiliation(s)
- Beth Russell
- Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King’s College London, London, United Kingdom
| | - Poppy Leech
- Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King’s College London, London, United Kingdom
| | - Harriet Wylie
- Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King’s College London, London, United Kingdom
| | - Charlotte Louise Moss
- Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King’s College London, London, United Kingdom
| | - Anna Haire
- Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King’s College London, London, United Kingdom
| | - Deborah Enting
- Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
| | - Suzanne Amery
- Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
| | - Kathryn Chatterton
- Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
| | | | - Ramesh Thurairaja
- Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
| | - Rajesh Nair
- Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
| | - Sachin Malde
- Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
| | - Kate Smith
- Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
| | - Cheryl Gillett
- King’s Health Partners Cancer Biobank, King’s College London, London, United Kingdom
| | - Debra Josephs
- Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
| | - Elias Pintus
- Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
| | - Sarah Rudman
- Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
| | - Simon Hughes
- Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
| | - Clare Relton
- Wolfson Institute of Population Health, Queen Mary University of London, London Sheffield, United Kingdom
| | - Mieke Van Hemelrijck
- Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King’s College London, London, United Kingdom
| |
Collapse
|